Dietary supplement label compliance is one of the most underestimated barriers to international growth: a 2025 NSF industry survey found that 62% of supplement brands experienced at least one border detention or label warning within their first three years of exporting. For OEM/ODM/CDMO customers selling across the U.S., EU, UK, Canada, and Australia, the regulatory frameworks differ sharply — what is permitted on a U.S. Dietary Supplement Facts panel can trigger a formal warning letter in the EU, and vice versa. This guide explains the core label requirements brands must satisfy before shipment, the documentation a compliant contract manufacturer should provide, and how to design labels that hold up across multiple jurisdictions without costly reprints.

Why Label Compliance Is a Strategic, Not Cosmetic, Concern

Label compliance sits at the intersection of regulatory law, consumer safety, and brand reputation. Unlike a packaging graphic mistake — which can be redesigned and reprinted in a few weeks — a non-compliant label can result in refused imports, mandated product recalls, or formal warning letters that are publicly searchable on regulator databases such as the U.S. FDA's Warning Letter index or the EU's SafetyGate (formerly RAPEX) system. For B2B brands distributing through Amazon, retail chains, or pharmacy networks, a single compliance failure can terminate a buyer relationship overnight.

For an OEM/ODM client, this means label compliance must be addressed during formulation development — not after the first production run. Reviewing ingredient admissibility, permitted structure/function claim wording, and country-specific allergen declarations before artwork is finalized saves both regulatory exposure and the cost of destroyed packaging inventory.

Key Components Every Supplement Label Must Include

What elements are mandatory on a U.S. Dietary Supplement Facts panel?

Under 21 CFR 101.36, every U.S. dietary supplement label must include: (1) a "Supplement Facts" heading with bold box-border formatting, (2) the serving size and servings per container declaration, (3) all dietary ingredients with their quantitative amounts per serving, (4) the % Daily Value (%DV) for vitamins and minerals listed at the 2016 updated RDIs, (5) the ingredient statement listing all components in descending order by weight, (6) the manufacturer or distributor name and physical address, and (7) the lot/batch identifier for traceability. Allergen disclosures for the "Big 9" (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, sesame — sesame added under the FASTER Act of 2023) must follow FALCPA rules, either in the ingredient statement or via a "Contains" statement immediately below it.

What does the EU require on a supplement label?

The EU framework layers several requirements: (1) the mandatory "Food Information to Consumers" data per Regulation (EU) 1169/2011 — including ingredient list with quantitative declaration for highlighted ingredients, allergen declarations, best-before date, batch number, and EU-based Responsible Person, (2) country-specific national notification — many member states (Germany, France, Italy, the Nordics, Belgium) require notification via the national competent authority portal before market placement, often 3-6 months in advance, (3) Novel Food compliance under Regulation (EU) 2015/2283 — any ingredient not used to a significant degree as a food in the EU before May 1997 must be explicitly authorized and listed on the Union list, and (4) Regulation (EC) 1924/2006 on nutrition and health claims — the EU permits only those claims listed in the EU Register of permitted nutrition claims and authorized health claims.

How do permitted claims differ between the U.S. and EU?

The U.S. follows a relatively permissive "structure/function" model under 21 CFR 101.93 and DSHEA 1994 — brands may state that a product "supports," "promotes," or "helps maintain" normal bodily function, provided the standard FDA disclaimer ("These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.") accompanies them. The EU is substantially stricter: every health claim referencing a physiological effect must be pre-authorized by EFSA and registered in the EU Register of Health Claims; unauthorized claims are illegal and can trigger swift regulatory action. Brands with a single SKU for both markets typically build two label variants and a shared master template that flags market-specific copy blocks.

Step-by-Step Compliance Workflow for OEM/ODM Brands

A repeatable label compliance workflow reduces regulatory risk at every stage. The typical six-step process at a cGMP-compliant contract manufacturer:

1. Pre-Formulation Regulatory Review — Ingredient admissibility check across target markets: Novel Food status in EU, GRAS status in U.S., ICCVAM/Health Canada requirements, TGA listing in Australia. Output: a target-market admissibility matrix per SKU.
2. Claim Strategy Approval — Each marketing claim is mapped to the strictest applicable regulation among target markets (the "lowest common denominator" approach). Claims management documentation records the legal basis — 21 CFR 101.93 in U.S., EU Register entry in EU, etc.
3. Master Artwork Build — Type-set the master artwork with placeholders for market-specific fields (Responsible Person address, importer of record, country-of-origin language, mandatory warnings). Maintaining one master per SKU simplifies version control.
4. Local Market Adaptation — Per-market artwork renders — for example, labeling requirement for Norwegian "Anbefalt døgndose", French-language panel for Canadian Quebec distribution, or Hebrew-language panel for Israel export. Each render must be reviewed by a regulatory consultant licensed in the destination country.
5. Pre-Print Proof Verification — Three-way reconciliation: artwork PDF, formulation record (master manufacturing batch record), and target-market legal review checklist. Discrepancies must be corrected before plates are cut.
6. Documentation Bundle Shipment — Every shipped lot should be accompanied by a Certificate of Analysis (CoA), a Certificate of Compliance, and allergen statements. For EU shipment, a signed Declaration of Conformity covering Regulation (EU) 1169/2011 is generally required at first import.

U.S. vs EU vs Canada Compliance: Side-by-Side Comparison

Frequently Asked Questions

Do I need an FDA registration number on my label?

If your finished product is manufactured in the U.S., the facility must be registered with the FDA under 21 CFR 1.300. For foreign manufacturers shipping to the U.S., FSVP (Foreign Supplier Verification Program) compliance is required, though the FSVP importer — not the manufacturer — typically holds the registration on file. Displaying the registration number on the label is not mandatory but is increasingly common for retailer compliance audits.

How long does it take to bring a new supplement SKU to compliance across 5 markets?

For a routine supplement (vitamins, minerals, herbal extracts already listed in each jurisdiction), expect 8-14 weeks of total workflow: 2 weeks for ingredient admissibility and claims review, 2-4 weeks for artwork production, 2-4 weeks for legal review per jurisdiction, and 2 weeks for pre-print reconciliation. Markets requiring pre-market authorization (EU notification, Canadian NHP license) add 3-9 months of lead time.

What documentation should my contract manufacturer provide at every shipment?

Minimum acceptable documentation: signed Certificate of Analysis covering identity, potency, and contaminants; signed Certificate of Compliance against specification; allergen statement matching label declarations; production batch record; and a retained sample sufficient for two independent analyses. For EU shipments, the Declaration of Conformity and import-ready documentation under the Responsible Person should also be available on request.

Can one label artwork serve multiple markets?

Yes — many brands use a "master plus overrides" model. The master artwork contains shared elements (brand name, product format, generic claims), while market-specific overrides generate country versions (e.g., German "Verzehrempfehlung", French "Doses quotidiennes recommandées", Hebrew warnings). This keeps version control manageable while satisfying local language and warning requirements.

What are the most common compliance mistakes brands make?

The three most frequent issues observed in 2024-2025 audit samples: (1) making unauthorized disease claims ("boosts immunity against flu", "prevents deficiency diseases") that cross the DSHEA line into drug claims, (2) using EU-only authorized ingredients in the U.S. without confirming GRAS or NDI status, and (3) missing updated allergen disclosure following the FASTER Act sesame requirement. Each of these is preventable through a structured claim and ingredient review during formulation.

Does SREKE handle compliance documentation for OEM/ODM/CDMO projects?

SREKE issues per-batch CoAs and Certificates of Compliance for every production lot, with documentation aligned to ISO 22000 and cGMP requirements. For brand customers targeting multiple jurisdictions, our regulatory team can coordinate ingredient admissibility reviews and connect you with country-specific regulatory consultants for final artwork sign-off. Allergen statements, nutritional composition data, and shelf-life stability summaries are bundled into shipment packages so your downstream records stay audit-ready.

How to Get Started with SREKE

Whether you are launching a single-SKU domestic launch or coordinating a multi-jurisdiction rollout across the U.S., EU, UK, Canada, and Australia, SREKE's regulatory team supports your compliance workflow from the first ingredient review through finished product documentation. We provide complete technical files, certificates, and stability evidence to keep your labels audit-ready across every market you enter. Bring us your formula or your finished concept — and we will produce a market-ready, compliance-cleared SKU on your timeline.

If you are looking for OEM/ODM/CDMO contract manufacturing services, please visit https://www.sreke.com/contact.php to submit your inquiry.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.